References
- Gladdy RA, Qin LX, Moraco N, Agaram NP, Brennan MF, Singer S.
Predictors of survival and recurrence in primary leiomyosarcoma.
Annals of surgical oncology. 2013; 20:1851-7.
- Imura Y, Takenaka S, Outani H, Nakai T, Yasuda N, Nakai S, Wakamatsu
T, Tamiya H, Okada S. Impact of Surgery and Chemotherapy on Metastatic
Extrauterine Leiomyosarcoma. Curr Oncol. 2022; 29(4):2301-2311.
- Yang J, Du X, Chen K, Ylipää A, Lazar AJ, Trent J, Lev D, Pollock R,
Hao X, Hunt K, Zhang W. Genetic aberrations in soft tissue
leiomyosarcoma. Cancer Lett. 2009; 275(1):1-8.
- Kyriazoglou A, Liontos M, Ntanasis-Stathopoulos I, Gavriatopoulou M.
The systemic treatment of uterine leiomyosarcomas: A systematic
review. No news is good news? Medicine (Baltimore). 2021;
100(13):e25309.
- Shoushtari AN, Landa J, Kuk D, Sanchez A, Lala B, Schmidt N, Okoli C,
Chi P, Dickson MA, Gounder MM, Keohan ML. Overall survival and
response to systemic therapy in metastatic extrauterine
leiomyosarcoma. Sarcoma. 2016; 2016.
- Barlin JN, Zhou QC, Leitao MM, Bisogna M, Olvera N, Shih KK, Jacobsen
A, Schultz N, Tap WD, Hensley ML, Schwartz GK. Molecular subtypes of
uterine leiomyosarcoma and correlation with clinical outcome.
Neoplasia. 2015; 17(2):183-9.
- Guo X, Jo VY, Mills AM, Zhu SX, Lee CH, Espinosa I, Nucci MR, Varma S,
Forgó E, Hastie T, Anderson S. Clinically relevant molecular subtypes
in leiomyosarcoma. Clinical cancer research. 2015; 21(15):3501-11.
- Oosten AW, Seynaeve C, Schmitz PI, Den Bakker MA, Verweij J, Sleijfer
S. Outcomes of first-line chemotherapy in patients with advanced or
metastatic leiomyosarcoma of uterine and non-uterine origin. Sarcoma.
2009; 2009.
- Lamm W, Natter C, Schur S, Köstler WJ, Reinthaller A, Krainer M, Grimm
C, Horvath R, Amann G, Funovics P, Brodowicz T, Polterauer S.
Distinctive outcome in patients with non-uterine and uterine
leiomyosarcoma. BMC Cancer. 2014; 14:981.
- Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt
C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K,
Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and
docetaxel versus doxorubicin as first-line treatment in previously
untreated advanced unresectable or metastatic soft-tissue sarcomas
(GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;
18(10):1397-1410.
- Tirumani SH, Deaver P, Shinagare AB, Tirumani H, Hornick JL, George S,
Ramaiya NH. Metastatic pattern of uterine leiomyosarcoma:
retrospective analysis of the predictors and outcome in 113 patients.
J Gynecol Oncol. 2014; 25(4):306-12.
- Farid M, Ong WS, Tan MH, Foo LS, Lim YK, Chia WK, Soh LT, Poon D, Lee
MJ, Ho ZC, Jeevan R, Chin F, Teo M, Quek R. The influence of primary
site on outcomes in leiomyosarcoma: a review of clinicopathologic
differences between uterine and extrauterine disease. Am J Clin Oncol.
2013; 36(4):368-74.
- Bartosch C, Afonso M, Pires-Luís AS, Galaghar A, Guimarães M, Antunes
L, Lopes JM. Distant Metastases in Uterine Leiomyosarcomas: The Wide
Variety of Body Sites and Time Intervals to Metastatic Relapse. Int J
Gynecol Pathol. 2017; 36(1):31-41.
- Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the
efficacy of chemotherapeutic regimens. Nature reviews Clinical
oncology. 2011; 8(3):151-60.
- Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the
efficacy of anticancer therapies. Trends Immunol. 2015;
36(4):198-216.
- Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, Kroemer G.
STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic
Chemotherapy by Stimulating Type 1 Interferon Production by Cancer
Cells. Cancer Res. 2015; 75(18):3812-22.
- Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt
SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY. Therapeutic
targeting of macrophages enhances chemotherapy efficacy by unleashing
type I interferon response. Nature cell biology. 2019; 21(4):511-21.